Bundles
Retatrutide Value Bundle
Includes 2 × Retatrutide 10mg + BAC Water 3ml + 0.5 mL Graduated Syringes 20 Pack
$320.96bought separatelySave $50.97Free express shipping
SKU 44595
$269.99
Buy Retatrutide 30 mg in Australia
Retatrutide 30 mg is a research-grade peptide that is studied in metabolic research, supplied in Australia by Australian Research Peptides to laboratories and researchers. It is the largest of three strengths ARP lists. The 30 mg vial is HPLC-tested and its certificate is published. Retatrutide is a laboratory-made peptide studied at three hormone receptors: GLP-1, GIP and glucagon. This 30 mg vial costs $299.99 and is in stock now, dispatched the same business day when paid before 12pm Sydney time, to all states and territories. For in vitro research purposes only.
Metabolic Research · Lyophilised Powder · HPLC-tested · SKU 39966
$299.99
Presentation
30 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Metabolic Research
Same-day dispatch on business-day orders completed before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide · typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, or usage information is provided.
Retatrutide bundles
Bundles
Retatrutide 20mg Starter Bundle
Includes Retatrutide 20mg + BAC Water 3ml + 0.5 mL Graduated Syringes 20 Pack
$260.97bought separatelySave $20.98Free express shipping
SKU 46426
$239.99
Bundles
Retatrutide Mega Bundle
Includes 3 × Retatrutide 10mg + 2 × BAC Water 3ml + 3 × 0.5 mL Graduated Syringes 20 Pack
$526.92bought separatelySave $106.93Free express shipping
SKU 41053
$419.99
Bundles
Retatrutide 4-Vial Bundle
Includes 4 × Retatrutide 10mg
$559.96bought separatelySave $109.97Free express shipping
SKU 43729
$449.99
About Retatrutide 30 mg
A single engineered chain of 39 amino acids reaching three separate receptor targets, where most peptides of the same structural family reach one or two. This is the 30 mg Retatrutide vial, the largest of three, listed as 39966.
The 30 mg certificate records 99.482% — measured on this lot, never carried across from the 10 mg and 20 mg vials.
In vitro metabolic research purposes only. Australian Research Peptides does not supply Retatrutide for human or veterinary use.
Retatrutide is studied in metabolic research. Eli Lilly developed the molecule and has carried it from early work through large late-stage studies. In laboratory receptor assays it binds the GIP, GLP-1 and glucagon receptors. That triple target separates it from the single-receptor GLP-1 analogues, which act at GLP-1 alone, and from the dual GIP/GLP-1 agonists, which act at two.
The molecule is one continuous chain of 39 amino acids, engineered from a GIP peptide backbone. The chain carries a C20 fatty di-acid, meaning a twenty-carbon fatty group bonded onto it. That group is described as binding albumin in blood, which is the design feature reported to make the molecule long-acting.
Australian Research Peptides supplies retatrutide as a freeze-dried solid, white to off-white, sealed in a tamper-evident glass vial. It is also written and searched as reta or retat. The material is a laboratory reference compound, characterised for benchwork in glassware and cell culture rather than for any use in a living subject.
In Australia, retatrutide is listed by Australian Research Peptides in three vial strengths — 10 mg, 20 mg and 30 mg — each with its own stock code and its own batch certificate. Anyone searching retatrutide Australia, reta peptide, or the numeric R3ta will land on the same triple-agonist compound under all of those names. Vials are held and posted domestically rather than shipped in from overseas, so an order is not waiting on international freight. Purity is assayed by HPLC, and the measured figure is published on each strength's own certificate rather than as a blanket claim about the line.
Retatrutide 30 mg specifications, storage and shipping
- Compound: Retatrutide
- Quantity: 30 mg
- SKU: 39966
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed to a minimum of 99% purity — the measured result is stated on the published Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Certificates: issued by Janoshik, an independent laboratory, and published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Retatrutide is HPLC-tested for purity and confirmed by mass spectrometry for identity. The full laboratory report is published in the COA library. Retatrutide is tested by Janoshik, an independent laboratory, commissioned by the manufacturer rather than by Australian Research Peptides.
- Retatrutide 30 mg: assayed purity 99.482% · measured content 33.05 mg · analysed 17 March 2026
Business-day orders before 12pm Sydney time are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about Retatrutide 30 mg
This Retatrutide 30 mg question guide from Australian Research Peptides is specific to the exact listing, with live buying details, size comparisons, concentration calculations, storage, testing and the inherited product background grouped separately. Start with the quick answers or jump to the topic you need.
Exact strength, quantity and listing fit
Three 10 mg Retatrutide vials cost $419.97; one 30 mg vial is $299.99 — $119.98 less, and two fewer vials to store.
Per milligram, Retatrutide 30 mg works out to about $10.00 — $299.99 across 30 mg. The 10 mg Retatrutide vial works out to about $14.00 a milligram.
Thirty milligrams of freeze-dried retatrutide, the largest listing Australian Research Peptides holds for this compound and three times the entry vial. Everything three small vials contain arrives under a single seal instead.
Extended or multi-arm work, where one seal covering the whole run matters more than keeping unopened vials in reserve. Once made up, the solution carries one storage history rather than three.
Live price, stock and Australian buying
Australian Research Peptides (ARP) sells Retatrutide 30 mg in Australia under 39966, at $299.99. Standard tracked post and Express Post carry Retatrutide 30 mg to all states and territories.
Retatrutide 30 mg is $299.99 a vial (39966). Two 30 mg vials come to $599.98.
Yes, on both services. One Retatrutide 30 mg vial at $299.99 passes $199 for free Standard tracked post, and $299 for free Express Post, with nothing else in the basket.
$299.99 delivered in Australia. Retatrutide 30 mg is $299.99, over both free-post marks, so 39966 by Standard tracked post or Express Post is still $299.99.
One. A single 30 mg Retatrutide vial is $299.99, already past $299, so free Express Post needs no second 30 mg vial beside 39966.
Reconstitution and concentration calculations
Australian Research Peptides publishes no fill volume for 39966, so the amount is a decision for the work rather than one the listing sets. 39966 is 30 mg of dry Retatrutide: what the diluent changes is the solution, never the 30 mg sealed in the glass.
Fixed costs per vial — glass, seal, label, packing, freight — do not rise with the powder inside, so spreading them across thirty milligrams lowers the rate. All three listings show their own figure, so the gap reads directly.
Product identity and research background
Retatrutide is a synthetic peptide of 39 amino acids, developed by Eli Lilly under the code LY3437943 (Coskun 2022) and studied in metabolic research. It is described as reaching the GIP, GLP-1 and glucagon receptors together, where single- and dual-receptor designs are the norm. The chain is one engineered molecule rather than a mixture of separate peptides, built on a GIP backbone with a twenty-carbon fatty di-acid bonded onto it. That fatty group is the part that makes it long-acting.
Retatrutide reaches three receptor targets at once. Published laboratory work describes the molecule binding at the GIP, GLP-1 and glucagon receptors, a combination that single- and dual-receptor designs do not have. Bonded onto the chain is a C20 fatty di-acid — a twenty-carbon fatty tail — and it binds albumin, the most common protein in blood, which is the structural feature the molecule was engineered around. Every statement here describes binding measured in glassware, not anything occurring in a living subject.
Retatrutide has 39 amino acids in one continuous synthetic chain. It is a single engineered molecule, not a blend of separate peptides mixed together. The chain is built from a GIP peptide backbone with a C20 fatty di-acid attached to it. No residue-by-residue sequence appeared in the public records checked. The milligram figure on the vial is weight, not a residue count.
Yes — Retatrutide is freeze-dried, and ten milligrams of dried peptide occupies almost no space: commonly a thin white disc, or a faint film on the glass base that overhead lighting washes out entirely. Tilting the container slowly against a dark surface usually reveals it. The 20 mg and 30 mg strengths carry two and three times that solid, so they read as an obvious cake. Weight rather than visible bulk is what batch analysis records.
Storage, condition and testing
Trapped air explains almost every cloudy Retatrutide vial. Directing the stream onto the cake, or shaking rather than swirling, whips tiny air bubbles through the liquid, and they scatter light exactly as real cloudiness does, then rise and disperse within a few minutes at rest. Cold glass slows the powder dissolving as well. Haze still present after ten minutes at room temperature points instead to solid that has not dissolved, or to peptide that has clumped together, and the 30 mg strength takes longest because it holds three times the material.
Retatrutide reaches three receptors and the dual agonists reach two. The dual agonists act at the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity on top of those two, and that third target is the entire difference between them. Australian Research Peptides lists Retatrutide for laboratories and researchers.
Delivery, payment and access questions
Retatrutide batches supplied by Australian Research Peptides go through two separate analyses at an independent laboratory, commissioned by the manufacturer, before they are sold, one measuring purity and the other confirming identity. HPLC produces the purity figure. Mass spectrometry then establishes that the molecule really is retatrutide and not something that presents identically as a dry powder. Identity is the one that matters here, because a shortened chain or a stripped fatty group still looks like white powder.
Retatrutide is also known by Eli Lilly's development code LY3437943 and is indexed under that code in trial registries and NIH MeSH record C000729679. It is commonly shortened to "Reta" in everyday use, which is a contraction of the same name rather than a different compound. It is sometimes nicknamed "Triple G" because it acts at GIP, GLP-1 and glucagon receptors; that nickname is informal, not a separate compound name. The label "GLP-3" is a misnomer rather than a synonym because Retatrutide does not involve a third GLP peptide.
More questions
Retatrutide has a published research literature in metabolic science, developed by Eli Lilly and reported in peer-reviewed journals (Jastreboff 2023). Australian Research Peptides publishes none of those figures on this page, because the material described in that literature is not the material in this vial. What ARP publishes instead is the batch's own certificate: identity and assay purity, measured by HPLC and confirmed by mass spectrometry, with the document itself in the CoA library.
A retatrutide vial holds one substance and nothing else. No carrier, no second peptide, no liquid. It is a freeze-dried solid, white to off-white, behind a tamper-evident seal. The C20 fatty di-acid is chemically bonded into the peptide chain rather than added alongside it, which is why the dry contents count as a single compound. The milligram figure on the listing is peptide weight.
Retatrutide should be kept sealed, cold and dry, away from moisture. The freeze-dried powder pulls water out of the air, so let a cold vial reach room temperature before you break the seal. Bachem's peptide handling guidance puts lyophilised material below -15 C for long-term storage and 4 C for short periods. Colder is better, and that guidance prefers -50 C or lower for long holdings.
Reconstituted retatrutide keeps at 2 to 8 °C for eight to twelve weeks. That is the storage condition Australian Research Peptides publishes for every HPLC Verified line it sells. Keep the solution dark, and never refreeze one that has thawed. For holds longer than that, Bachem and GenScript both advise splitting it into single-use aliquots and freezing them below -15 °C.
Australian Research Peptides Pty Ltd, trading as ARP, is the supplier of retatrutide in Australia, an Australian company dispatching from Sydney. The compound is catalogued under Metabolic Research by its development code LY3437943, and its purity is tested by HPLC. PayID and bank transfer are the routes accepted — no buy-now-pay-later and no crypto.
Retatrutide is not approved for therapeutic use by the TGA, or by any other regulator worldwide. Eli Lilly describes it as an investigational molecule, legally available only to people enrolled in its own clinical trials. Australian Research Peptides supplies it as a laboratory research chemical, not as a medicine, and not for use in people or animals. Check your own obligations before handling it.
Retatrutide holds no approval from the US Food and Drug Administration, nor from any other medicines regulator anywhere. Eli Lilly still describes it as an investigational molecule. Its development programme is still running, which is a step toward a submission rather than a licence in itself. Research-grade powder sits a further step removed, assessed by no one at all.
Retatrutide is banned for any tested athlete. Still investigational, with no approval from a government health regulator, it falls inside category S0 — the sweep capturing investigational molecules — and that ban runs year-round, not merely on competition day. Australian competitors are governed by Sport Integrity Australia, where a positive sample counts whatever the athlete intended.
Retatrutide remains an investigational molecule rather than an approved commercial medicine on sale to the Australian public. Australian Research Peptides does not supply it as a compounded prescription item or a pharmacy medicine, and because no regulator has approved it, no Australian compounding pharmacy can lawfully make it up either — what ARP supplies is research-grade freeze-dried powder for lawful in vitro laboratory work only. Eli Lilly still describes the molecule as investigational with its development programme running, so commercial release would depend on that programme finishing and a regulator then granting approval. No launch date has been published.
Retatrutide is described as acting at three receptors and the single-receptor GLP-1 peptides at one. Retatrutide is described in the literature as a triple agonist, at the GIP, GLP-1 and glucagon receptors. The GLP-1-only class is described as working at the GLP-1 receptor alone. They are separate molecules with different sequences and different weights, and Australian Research Peptides catalogues Retatrutide rather than that class.
The three Retatrutide listings hold the same material in different quantities. The number is milligrams of peptide sitting in the glass. Colour, container, closure and the testing method do not change between them. Australian Research Peptides gives every strength its own page and its own stock code, and all three sit under one parent listing.